Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

被引：121

作者：

Hu, Yongxian ^{[1
,2
,3
,4
]}

Zhou, Yali ^{[5
,6
]}

Zhang, Mingming ^{[1
,2
,3
,4
]}

Zhao, Houli ^{[1
,2
,3
,4
]}

Wei, Guoqing ^{[1
,2
,3
,4
]}

Ge, Wengang ^{[5
]}

Cui, Qu ^{[7
]}

Mu, Qitian ^{[8
]}

Chen, Gong ^{[5
]}

Han, Lu ^{[5
]}

Guo, Tingting ^{[5
]}

Cui, Jiazhen ^{[1
,2
,3
,4
]}

Jiang, Xiaoyan ^{[5
]}

Zheng, Xiujun ^{[5
]}

Yu, Shuhui ^{[5
]}

Li, Xiaolong ^{[5
]}

Zhang, Xingwang ^{[5
]}

Chen, Mingxi ^{[5
]}

Li, Xiuju ^{[5
]}

Gao, Ming ^{[5
]}

Wang, Kang ^{[5
]}

Zu, Cheng ^{[1
,2
,3
,4
]}

Zhang, Hao ^{[6
]}

He, Xiaohong ^{[5
]}

Wang, Yanbin ^{[5
]}

Wang, Dongrui ^{[1
,2
,3
,4
]}

Ren, Jiangtao ^{[5
]}

Huang, He ^{[1
,2
,3
,4
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China

[4] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Zhejiang, Peoples R China

[5] Nanjing Bioheng Biotech Co Ltd, Nanjing, Jiangsu, Peoples R China

[6] Ruian Peoples Hosp, Dept Hematol, Wenzhou, Zhejiang, Peoples R China

[7] Capital Med Univ, Beijing Tiantan Hosp, Dept Hematol, Beijing, Peoples R China

[8] Ningbo First Hosp, Lab Stem Cell Transplantat, Ningbo, Zhejiang, Peoples R China

来源：

CELL RESEARCH | 2022年 / 32卷 / 11期

基金：

中国国家自然科学基金;

关键词：

CHIMERIC ANTIGEN RECEPTOR; EXPRESSION; LEUKEMIA; 1ST-IN-HUMAN; MANAGEMENT; ADULTS;

D O I：

10.1038/s41422-022-00721-y

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Chimeric antigen receptor (CAR)-T cell therapy against T cell malignancies faces major challenges including fratricide between CAR-T cells and product contamination from the blasts. Allogeneic CAR-T cells, generated from healthy donor T cells, can provide ready-to-use, blast-free therapeutic products, but their application could be complicated by graft-versus-host disease (GvHD) and host rejection. Here we developed healthy donor-derived, CD7-targeting CAR-T cells (RD13-01) with genetic modifications to resist fratricide, GvHD and allogeneic rejection, as well as to potentiate antitumor function. A phase I clinical trial (NCT04538599) was conducted with twelve patients recruited (eleven with T cell leukemia/lymphoma, and one with CD7-expressing acute myeloid leukemia). All patients achieved pre-set end points and eleven proceeded to efficacy evaluation. No dose-limiting toxicity, GvHD, immune effector cell-associated neurotoxicity or severe cytokine release syndrome (grade >= 3) were observed. 28 days post infusion, 81.8% of patients (9/11) showed objective responses and the complete response rate was 63.6% (7/11, including the patient with AML). 3 of the responding patients were bridged to allogeneic hematopoietic stem cell transplantation. With a median follow-up of 10.5 months, 4 patients remained in complete remission. Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) reactivation was observed in several patients, and one died from EBV-associated diffuse large B-cell lymphoma (DLBCL). Expansion of CD7-negative normal T cells was detected post infusion. In summary, we present the first report of a Phase I clinical trial using healthy donor-derived CD7-targeting allogeneic CAR-T cells to treat CD7(+) hematological malignancies. Our results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7(+) tumors.

引用

页码：995 / 1007

页数：13

共 34 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies [J].

Benjamin, Reuben ;

Graham, Charlotte ;

Yallop, Deborah ;

Jozwik, Agnieszka ;

Mirci-Danicar, Oana C. ;

Lucchini, Giovanna ;

Pinner, Danielle ;

Jain, Nitin ;

Kantarjian, Hagop ;

Boissel, Nicolas ;

Maus, Marcela V. ;

Frigault, Matthew J. ;

Baruchel, Andre ;

Mohty, Mohamad ;

Gianella-Borradori, Athos ;

Binlich, Florence ;

Balandraud, Svetlana ;

Vitry, Fabien ;

Thomas, Elisabeth ;

Philippe, Anne ;

Fouliard, Sylvain ;

Dupouy, Sandra ;

Marchiq, Ibtissam ;

Almena-Carrasco, Maria ;

Ferry, Nicolas ;

Arnould, Sylvain ;

Konto, Cyril ;

Veys, Paul ;

Qasim, Waseem .

LANCET, 2020, 396 (10266) :1885-1894

[3] CAR T cell therapy: inroads to response and resistance [J].

Brown, Christine E. ;

Mackall, Crystal L. .

NATURE REVIEWS IMMUNOLOGY, 2019, 19 (02) :73-74

[4]

CAMPANA D, 1991, BLOOD, V77, P1546

[5] CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype [J].

Chang, Hong ;

Yeung, Joanna ;

Brandwein, Joseph ;

Yi, Qi-Long .

LEUKEMIA RESEARCH, 2007, 31 (02) :157-162

[6] Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy [J].

Chou, Cassie K. ;

Turtle, Cameron J. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) :653-664

[7] 'Off-the-shelf' allogeneic CAR T cells: development and challenges [J].

Depil, S. ;

Duchateau, P. ;

Grupp, S. A. ;

Mufti, G. ;

Poirot, L. .

NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) :185-199

[8] Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions [J].

Fleischer, Lauren C. ;

Spencer, H. Trent ;

Raikar, Sunil S. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)

[9] Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia [J].

Fraietta, Joseph A. ;

Lacey, Simon F. ;

Orlando, Elena J. ;

Pruteanu-Malinici, Iulian ;

Gohil, Mercy ;

Lundh, Stefan ;

Boesteanu, Alina C. ;

Wang, Yan ;

O'Connor, Roddy S. ;

Hwang, Wei-Ting ;

Pequignot, Edward ;

Ambrose, David E. ;

Zhang, Changfeng ;

Wilcox, Nicholas ;

Bedoya, Felipe ;

Dorfmeier, Corin ;

Chen, Fang ;

Tian, Lifeng ;

Parakandi, Harit ;

Gupta, Minnal ;

Young, Regina M. ;

Johnson, F. Brad ;

Kulikovskaya, Irina ;

Liu, Li ;

Xu, Jun ;

Kassim, Sadik H. ;

Davis, Megan M. ;

Levine, Bruce L. ;

Frey, Noelle V. ;

Siegel, Donald L. ;

Huang, Alexander C. ;

Wherry, E. John ;

Bitter, Hans ;

Brogdon, Jennifer L. ;

Porter, David L. ;

June, Carl H. ;

Melenhorst, J. Joseph .

NATURE MEDICINE, 2018, 24 (05) :563-+

[10] CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia [J].

Gomes-Silva, Diogo ;

Atilla, Erden ;

Atilla, Pinar Ataca ;

Mo, Feiyan ;

Tashiro, Haruko ;

Srinivasan, Madhuwanti ;

Lulla, Premal ;

Rouce, Rayne H. ;

Cabral, Joaquim M. S. ;

Ramos, Carlos A. ;

Brenner, Malcolm K. ;

Mamonkin, Maksim .

MOLECULAR THERAPY, 2019, 27 (01) :272-280

← 1 2 3 4 →